Gefitinib

Active Ingredient: Gefitinib
Form: Oral tablet
Brand Name: Iressa
Generic Name: Gefikin
Generic Manufacturer: Ziska Pharmaceuticals

Indications:
Iressa is indicated as first-line treatment for metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as confirmed by an FDA-approved test.

Dosage and Administration:
The recommended dose is 250 mg orally once daily, with or without food. For patients with swallowing difficulties, the tablet may be dispersed in 4 to 8 ounces of water and taken within 15 minutes. If a dose is missed, do not take it within 12 hours of the next scheduled dose.

Common Side Effects:
Interstitial lung disease, hepatotoxicity, gastrointestinal perforation, prolonged or severe diarrhea, and eye or skin disorders.

Storage:
Store at 20–25°C in a cool, dry place away from direct sunlight. Keep out of reach of children.

Frequently Asked Questions

Q: What is the relationship between Iressa and Gefitinib?
A: Iressa is the brand name registered by the original manufacturer. Gefitinib is its active ingredient.

Q: Is the Iressa sold by Mediva Rx the original brand-name drug?
A: No. Mediva Rx offers a high-quality generic version manufactured by one of Bangladesh’s top 10 pharmaceutical companies. It contains the same active ingredient and therapeutic effect as the original drug, and is tested and approved by the Directorate General of Drug Administration (DGDA).

Q: Is the manufacturer of this generic version reliable?
A: Yes. We work with Ziska Pharmaceuticals, a leading Bangladeshi pharmaceutical company with in-house R&D, production, and quality control labs. They are certified for international pharmaceutical manufacturing standards. You can purchase with confidence.

Q: What is the target of Iressa, and who is it suitable for?
A: Iressa targets the EGFR mutation and is specifically suitable for NSCLC patients with confirmed EGFR exon 19 deletions or exon 21 (L858R) mutations. It is not effective for patients with KRAS mutations. If KRAS-targeted therapy is unsuitable for you, refer to our “Lung Adenocarcinoma Targeted Therapy Guide” for appropriate alternatives.

Disclaimer:
This information is for reference only. Treatment decisions should be made in consultation with your physician, based on the official medication guide and the latest clinical evidence.

Drug Instructions (Package Insert):
Download Link